We had reported that the lipofibrotic and muscle mass inhibitor, myostatin, was overexpressed in male MDSC undergoing in vivo damage by T2D/O [19] and in vitro by dyslipidemic serum [18], in concordance with down-regulation of miRs that counteract myostatin expression in vivo. The gene discussed is MSTN; the disease is type 2 diabetes mellitus.